SQUAWK/NEWS
Account
Theme
Account
Menu
Live News REGULATION ARTICLE M impact

GSK Wins Early FDA Approval for Nelkarmi Lung Cancer Drug

The FDA approved Nelkarmi ahead of its original decision deadline, based on Phase I/II ALKOVE-1 trial data showing clinically meaningful, durable responses in patients previously treated with ALK inhibitors.

GSK

The approval came ahead of the FDA's original decision deadline and was based on data from the ALKOVE-1 Phase I/II trial, which demonstrated clinically meaningful and durable responses in patients who had previously received ALK inhibitor therapies. GSK said the next-generation treatment was specif…

Related stories